Swiss Dental Startup vVARDIS Lists on NYSE Under Ticker VVVV
vVARDIS debuts on the New York Stock Exchange with a drill-free cavity treatment targeting the world's most common non-communicable disease.
Swiss dental biotech vVARDIS began trading on the New York Stock Exchange under the ticker symbol VVVV on Nov. 13, 2026, marking a significant milestone for a company that has built its identity around eliminating the dental drill from cavity treatment.
The company was co-founded by Dr. Haley Abivardi and Dr. Goly Abivardi, who have positioned vVARDIS around a core scientific premise: that cavities, widely recognized as the world's most prevalent non-communicable disease, can be addressed without the invasive procedures that have defined dentistry for generations. Their drill-free approach represents the central commercial and medical proposition behind the public listing.
Read more Stark Future Raises €150M+ as Electric Enduro Bikes Lead Market →
The NYSE debut places vVARDIS among a growing class of health-focused companies seeking capital markets access to accelerate product development and global distribution. A public listing of this nature typically provides a company with greater visibility among institutional investors and a currency — publicly traded shares — that can be used for partnerships, acquisitions, and expansion.
Cavities affect an estimated billions of people worldwide, and the dental industry has long faced criticism for treatment models that are reactive rather than preventive. By framing its technology as a solution to a near-universal health burden, vVARDIS is signaling ambitions that extend well beyond a niche market.
Continue reading at All Financial Services & Investing.